Bile acids have been incriminated in the pathogenesis of reflux gastritis, also in patients not submitted to gastric surgery. Their damaging effect on the gastric mucosa is different, UDCA being less noxious than other bile acids. Thirty patients with superficial alkaline reflux gastritis were randomly treated with ursodeoxycholic acid (UDCA) (150 mg b.i.d.) or placebo for 12 weeks in a double-blind controlled trial. Total bile acids in the gastric samples were measured to confirm duodenogastric reflux. The severity of dyspeptic symptoms and the grade of endoscopic and histological gastritis were assessed before treatment and at the end of the study. No differences were found between UDCA and placebo as for their effects on symptoms, endoscopic and histological features. However a statistically significant effect of both UDCA and placebo was found when clinical reports at 6 and 12 weeks and endoscopic and histological features at 12 weeks were compared with the corresponding pre-treatment findings. The considerable " placebo effect " observed in our study makes the results inconclusive. Whether UDCA would be beneficial in the treatment of reflux gastritis in patients not submitted to gastric surgery needs further evaluation in larger series of subjects.
|Translated title of the contribution||Double-blind controlled trial of ursodeoxycholic acid (UDCA) versus placebo in the treatment of reflux gastritis in patients not submitted to gastric surgery|
|Number of pages||10|
|Publication status||Published - Jul 1989|
- reflux gastritis
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging